Lisa Davis, PharmD, FCCP, BCPS, BCOP

Clinical Professor

Lisa E. Davis, PharmD, FCCP, BCPS, BCOP, professor, Department of Pharmacy Practice and Science—specializes in adult medical oncology. Davis’ work includes Early Phase Clinical Trials at the University of Arizona Cancer Center where she is also a member of the Cancer Prevention and Control Program.

Dr. Davis is board certified in pharmacotherapy and oncology pharmacotherapy. Her research interests include drug development, drug resistance, pharmacokinetics, and other factors that influence drug disposition and response.

View UA Profile

Education & Post Graduate Training: 

Fellowship, Oncology Pharmacotherapy, University of Arizona, 1987
Residency, Clinical Pharmacy Residency, University Medical Center (Tucson, AZ)
PharmD, University of Kentucky, 1984
BS, Pharmacy, University of Arizona, 1983

Clinical Expertise: 

Supportive care

Areas of Research: 

Breast cancer
Colon cancer
Cancer prevention
Multiple myeloma
Medication adherence
Supportive care
Drug development
Adult malignancies

Types of Research: 
Behavioral Research
Clinical Trials

Select Publications


Haas NB, Appleman LJ, Stein M, et al. "Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma." Clin. Cancer Res.. 2019;25(7):2080-2087. PMID: 30635337


Rangwala R, Chang YC, Hu J, et al. "Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma." Autophagy. 2014;10(8):1391-402. PMCID: PMC4203516  PMID: 24991838
Vogl DT, Stadtmauer EA, Tan K-S, et al. "Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma." Autophagy. 2014;10(8):1380-90. PMCID: PMC4203515  PMID: 24991834
Rosenfeld MR, Ye X, Supko JG, et al. "A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme." Autophagy. 2014;10(8):1359-68. PMCID: PMC4203513  PMID: 24991840
Rangwala R, Leone R, Chang YC, et al. "Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma." Autophagy. 2014;10(8):1369-79. PMCID: PMC4203514  PMID: 24991839
Hartman R, Blustein L, Morel D, Davis L. "A pharmaceutical industry elective course on practice experience selection and fellowship pursuit by pharmacy students." Am J Pharm Educ. 2014;78(6):126. PMCID: PMC4140492  PMID: 25147398